Some long-overdue news. After years covering EVs, batteries & the energy transition, I’m shifting gears. I’ve joined @Endpts News as Head of Signal — building a new intelligence platform from scratch. Back to my roots in the weird, brilliant, high-stakes world of drug science🧬1/

When Tesla unveiled the Model 3 in 2016, battery prices were more than 3x what they are today. Imagine what will be possible 10 years from now.

Battery prices at $108/kWh is wild to see. That's the global average for all-in pack prices. In China, where EV and solar+battery adoption continues to rip, pack prices are down to $84/kWh. Latest figures from BNEF: https://t.co/3FPLG1iEuB

Every time the quantity of batteries in the world doubles, prices fall 18%. This experience curve is one of the most consistent, and consequential, guideposts for predicting the future of energy and transportation.

A year from now, if the biopharma industry finds itself on much more solid footing, we may look back at this as the moment the gloom finally lifted. https://t.co/AlWk2hP8eM

During the two weeks that our biopharma sentiment survey was in the field in mid-October, something unusual happened: The mood of the industry appeared to snap out of its despair, all at once. Our survey caught it real time.

Experience with AI matters a great deal for how quickly people think drug development will evolve: 90% of extensive users see transformational change in five years versus just 18% of people who don't use AI today https://t.co/3ETT8XFdMh

Three quarters of people in biopharma expect AI to transform drug R&D by 2030 — and 12% think we’ll get there even sooner, in just three years. Already 48% are heavy users of AI in their daily work, according to our latest pulse poll.

@BowTiedBiotech I've been elbows-deep building tools and mapping out the benchmark products that will define @endpts Signal—and I can't wait to share what's coming. Let me know what you think https://t.co/5lrMhJ6NH8 https://t.co/FASsOfAguv

@BowTiedBiotech There’s a lot more to explore in the BPSI — I’d love to hear what you think. This is just setting the baseline. Future installments will show how sentiment changes over time and how those changes anticipate other metrics of industry performance 7/

@BowTiedBiotech Pharma execs are also a lot more optimistic than the people who work for them. That may be in part because the 5-year drought in dealmaking may be coming to an end, and from Boston to Wuxi, there are a lot of attractive deals to be made 6/ https://t.co/PNVFjrouo0

@BowTiedBiotech China’s biopharma mood is much more upbeat than in the US. This won’t be a shock to anyone who's been watching the recent differences in government support for life science. Flows of capital and brainpower are moving east 5/ https://t.co/PNVFjrouo0

Biopharma sentiment was more upbeat the farther the organization’s focus veered from the lab. Academics were despondent, while investors were practically ebullient about the next 12 months. @BowTiedBiotech made an A+ meme out of this table 😂 4/

Expectations for next year still tilt negative—but much better. The decoupling between current & 12-month expectations is where the action is: It suggests confidence may be returning ahead of fundamentals. Top reason for optimism: pace of innovation 3/ https://t.co/PNVFjrouo0

Just look at these assessments of current conditions in biopharma. Policy risk is the dominant force shaping sentiment in biopharma — 83% say things have gotten worse. Reasons for pessimism? The top five all trace back to questions of governance 2/ https://t.co/PNVFjrouo0

@ArmstrongDrew @AKAarsalan @endpts This week we’re launching Signal with a few projects I’m very proud of. You can find them at the Signal homepage: https://t.co/Vdnf4ciwGF, or follow along in this separate thread:

Introducing the Biopharma Sentiment Index, a quarterly benchmark measuring the mood of the industry. It includes the viewpoints of 1,457 verified respondents, a quarter of whom are C-level execs. Current conditions? Brutal. Future expectations: Better. The BPSI shows why

Best of all, I'm reunited with @armstrongdrew, one of the finest journalists+collaborators around. And team up with @AKAarsalan, the unstoppable force behind one of the most beloved brands in life sciences. And join the ridiculously talented band of merry pirates @endpts 3/

For those who only know me as the EVs/batteries guy: This is less of a pivot than it looks. I began my career covering health & science, and biotech has always been one of the most fascinating corners of the innovation economy. Hope you’ll follow along 2/ https://t.co/0hmcBKoQ86

4/ Tesla’s ambitions now go well beyond cars: Musk says EVs will be dwarfed by clean energy, robotaxis, humanoid robots—much like Nvidia moved past gaming chips and Amazon books. But worth noting: Those companies maintained their core market majorities 4/